ClinicalTrials.gg
CompletedNCT03370874Updated Aug 25, 2023

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

A Phase 3 interventional study of ALLO-ASC-DFU and Vehicle sheet in Diabetic Foot Ulcer, sponsored by Anterogen Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by Anterogen Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Diabetic Foot by Anterogen Co., Ltd. — 2 open to participants now, 2 under way, none of them phase 3. Diabetic Foot · Anterogen Co., Ltd..

Started
2018
the only one that year
Phase 3
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Diabetic Foot by Anterogen Co., Ltd., this one is the only one that started in 2018, is one of 2 in phase 3, and was the 5th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

2 of the 10 studies in Diabetic Foot by Anterogen Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 138 Diabetic Foot studies recruiting now, 97 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetic Foot by Anterogen Co., Ltd., or all of them as a file.
02

Study summary

This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to placebo therapy.

Read the detailed description

Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional, Study design: Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18 and 75 years of age.
  2. Subject is diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer than 4 weeks at the screening visit.
  3. Foot ulcer size is between 1 cm2 and 15 cm2
  4. Ulcer graded I or II by Wagner grade, and extended to skin, tendon, and subcutaneous tissue.
  5. Free of necrotic debris at target ulcer
  6. Around ulcer area blood circulation should be secured to meet one of below criteria;

    • Blood vessels around the ulcer detected by Doppler Test
    • 0.7 \< Ankle Brachial Index(ABI) \< 1.3
    • Transcutaneous Oxygen Pressure, TcPO2 higher than 30 mmHg
  7. Subject is able to give written prior to study start and to comply with the study requirements during study.

Exclusion criteria

Exclusion Criteria:

  1. Non-diabetic pathophysiologic ulcer.
  2. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.
  3. Subjects requiring intravenous (IV) antibiotics to treat infection.
  4. Current evidence of infection including pus drainage from the wound site.
  5. Subject has a A1c (HbA1c) level of > 15%
  6. Subject's blood sugar is > 450 mg/dl at postprandial.
  7. Subjects with severe renal failure that cannot be managed by renal dialysis.
  8. Subjects with severe hepatic deficiencies.
  9. Subject is (HIV) positive.
  10. Subject who has allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.
  11. Subject who is pregnant or breast-feeding.
  12. Subjects who are unwilling to use an "effective" method of during the study.
  13. Subjects who have a history of alcohol or drugs abuse.
  14. Subjects who are not able to understand the objective of this study or to comply with the study requirements.
  15. Subjects who are considered to have a significant disease which can impact the study by investigator.
  16. Subjects who are considered not suitable for the study by investigator.
  17. Subjects who had had a history of surgery for malignant tumor within the last five years (except carcinoma in situ).
  18. Subjects who are currently or are enrolled in another clinical study within 60 days of screening.
  19. Subjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.
  20. Subjects who are receiving oral or parenteral , , or cytotoxic agents with unstable dose prior to 4 weeks from screening.
  21. Subjects not comply with off-loading procedure
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    ALLO-ASC-DFU

    Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells

    Biological: ALLO-ASC-DFU

  • Placebo comparator
    Vehicle Sheet

    Hydrogel sheet without Allogenic mesenchymal stem cell

    Procedure: Vehicle sheet

Interventions

06

What researchers measure

Primary outcomes

  1. Proportions of subjects who achieved complete wound closure

    Time frame: During 12 weeks

Secondary outcomes

  1. Time taken to complete wound closure between the two groups

    Time frame: During 12 weeks

  2. Proportions of subjects who achieved complete wound closure

    Time frame: Follow up to 12 weeks

  3. Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups

    Time frame: Follow up to 12 weeks

  4. Change rates in wound size and depth compared to baseline between the two groups

    cm\^2

    Time frame: During 12 weeks

  5. Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations

    Time frame: Follow up to 12 weeks

07

Study locations

1 site
  • Korea University Kuro Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Dec 2019, 17 months.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2017
First posted
Dec 13, 2017
StartActual
Jun 27, 2018
Primary completionActual
Dec 9, 2019
CompletionActual
Feb 20, 2020
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03370874
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Jun 27, 2018
Primary completion
Dec 9, 2019
Completion
Feb 20, 2020
Last update
Aug 25, 2023

Study contacts

Seung-Kyu Han, MD. Ph D.
principal investigator · Korea University Guro Hospital
Ki-Won Young, MD. Ph D.
principal investigator · Eulji General Hospital
Junpyo Hong, MD. Ph D.
principal investigator · Asan Medical Center
Donghyeok Shin, MD. Ph D.
principal investigator · Konkuk University Medical Center
Junhyeong Kim, MD. Ph D.
principal investigator · Keimyung University Dongsan Medical Center
Kang Chan, MD. Ph D.
principal investigator · Chungnam National University Hospital
Hyungmin Hahn, MD. Ph D.
principal investigator · Ajou University Medical Center
Changsik Park, MD. Ph D.
principal investigator · Seoul National University Bundang Hospital
Youngkoo Lee, MD. Ph D.
principal investigator · Soonchunhyang University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Adipose-derived Mesenchymal Stem Cells

Start the discussion